<DOC>
	<DOCNO>NCT00613028</DOCNO>
	<brief_summary>Primary objective To estimate 6-month progression free survival probability pt w recurrent GBM treat w bev + either daily temozolomide/etoposide follow progression bev + irinotecan Secondary Objectives To evaluate safety &amp; tolerability bev + either daily temozolomide/etoposide among pt w recurrent GBM progress bev + irinotecan To evaluate radiographic response , progression free survival &amp; overall survival pt w recurrent GBM treat w bev + either daily temozolomide/etoposide follow progression bev + irinotecan</brief_summary>
	<brief_title>Ph II Bev + Either Temozolomide/Etoposide GBM Pts Who Have Failed Bev + Irinotecan</brief_title>
	<detailed_description>This exploratory , two-arm , phase II study design assess anti-tumor activity bev + either daily temozolomide/etoposide among GBM pt w progressive disease follow bev + irinotecan . About 48 participant w recurrent GBM take part study . Approximately 24 participant receive bev plus temozolomide &amp; approximately 24 receive bev + etoposide . Pts must confirm diagnosis GBM &amp; radiographic evidence recurrence follow prior therapy bev + irinotecan . 24 pt enrol onto arm single-stage study . If 4 24 pt live 6/more month without disease progression , treatment regimen consider worthy investigation . Otherwise , treatment regimen determine worthy investigation within pt population . Type I &amp; II error rate associate w test 0.030 &amp; 0.115 respectively . Management guideline dose reduction/interruption temo , etoposide , &amp; bev .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Pts confirm diagnosis GBM &amp; radiographic evidence recurrence follow prior therapy w bev + irinotecan Age &gt; 18 yr Interval &gt; 4 wks prior surgical resection/1 week stereotactic biopsy Interval &gt; 12 wks end prior external beam radiation therapy ( XRT ) unless new area enhancement consistent w recurrent tumor outside XRT field , /there progressive change MRI &gt; 2 consecutive MRI scan &gt; 4wks apart , /there biopsyproven tumor progression Interval &gt; 4 wks prior chemo / investigational agent unless pt recover anticipated toxicity associate w therapy . Eastern Cooperative Oncology Group ( ECOG ) 01 Hematocrit &gt; 29percent , absolute neutrophil count ( ANC ) &gt; 1,000 cells/ml l , platelet &gt; 100,000 cells/ml l Serum creatinine &lt; 1.5 mg/dl , serum glutamate oxaloacetate transaminase ( SGOT ) &amp; bilirubin &lt; 1.5 time upper limit normal ( ULN ) Signed informed consent approve Institutional Review Board ( IRB ) prior pt entry No evidence hemorrhage baseline MRI/CT scan stable gr1 If sexually active , pt take contraceptive measure duration treatment Comedication may interfere w study result Active infection require intravenous antibiotic Progression daily etoposide/progression daily temo Gr3/greater toxicity relate prior bev therapy , /prior temozolomide/etoposide Requires therapeutic anticoagulation warfarin . Inability comply w study and/or followup procedure Current , recent , /planned participation experimental drug study Genentechsponsored bev cancer study Inadequately control hypertension Any prior history hypertensive crisis/hypertensive encephalopathy New York Heart Association ( NYHA ) Gr II/greater congestive heart failure History myocardial infarction ( MI ) /unstable angina within 6 mths prior study enrollment History stroke/transient ischemic attack within 6 mths prior study enrollment Significant vascular disease Symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment Serious , nonhealing wound , ulcer , bone fracture Proteinuria screening demonstrate either : urine protein : creatinine ( UPC ) ratio &gt; 1.0 screen / Urine dipstick proteinuria â‰¥ 2+ Known hypersensitivity component bevacizumab Pregnant lactating . Use effective mean contraception subject childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>GBM</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Temodar</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Etopophos</keyword>
	<keyword>Toposar</keyword>
	<keyword>VePesid</keyword>
	<keyword>VP-16</keyword>
	<keyword>Camptosar</keyword>
</DOC>